CBLB

Across TCGA pan-cancer cohorts, CBLB mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CBLB data layer compared with 22 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CBLB mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CBLB expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where CBLB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	1.000	0.811	.004	21	view →
LSCC	OS	Tertile	All	1.000	0.911	.012	9	view →
CCRCC	OS	Quartile	All	0.815	1.000	.032	5	view →
HNSC	OS	Median	All	0.892	0.798	.031	2	view →
GBM	OS	Quartile	All	0.739	0.943	.005	2	view →
LUAD	OS	Quartile	All	0.669	1.000	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CBLB–PDAC (OS)

Open the PDAC breakdown →